Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 2
2020 1
2021 3
2022 4
2023 3
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer.
Elez E, Yoshino T, Shen L, Lonardi S, Van Cutsem E, Eng C, Kim TW, Wasan HS, Desai J, Ciardiello F, Yaeger R, Maughan TS, Morris VK, Wu C, Usari T, Laliberte R, Dychter SS, Zhang X, Tabernero J, Kopetz S; BREAKWATER Trial Investigators. Elez E, et al. N Engl J Med. 2025 Jun 26;392(24):2425-2437. doi: 10.1056/NEJMoa2501912. Epub 2025 May 30. N Engl J Med. 2025. PMID: 40444708 Free PMC article. Clinical Trial.
An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study.
Xu C, Mannucci A, Esposito F, Oliveres H, Alonso-Orduña V, Yubero A, Fernández-Martos C, Salud A, Gallego J, Martín-Richard M, Fernández-Plana J, Guillot M, Aparicio J, Fakih M, Kopetz S, Feliu J, Maurel J, Goel A. Xu C, et al. Among authors: oliveres h. Clin Cancer Res. 2025 Mar 17;31(6):1002-1015. doi: 10.1158/1078-0432.CCR-24-1934. Clin Cancer Res. 2025. PMID: 39820673 Free PMC article.
New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer.
Janssens K, Lambrechts C, Geerinckx B, Op de Beeck K, Van Camp G, Oliveres H, Prenen H, Vandamme T, Peeters M. Janssens K, et al. Among authors: oliveres h. Curr Treat Options Oncol. 2023 Aug;24(8):965-987. doi: 10.1007/s11864-023-01095-y. Epub 2023 May 22. Curr Treat Options Oncol. 2023. PMID: 37212934 Review.
Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53-Mutated Metastatic Colorectal Cancer.
Lahoz S, Rodríguez A, Fernández L, Gorría T, Moreno R, Esposito F, Oliveres H, Albiol S, Saurí T, Pesantez D, Riu G, Cuatrecasas M, Jares P, Pedrosa L, Pineda E, Postigo A, Castells A, Prat A, Maurel J, Camps J. Lahoz S, et al. Among authors: oliveres h. Cancers (Basel). 2022 Nov 30;14(23):5921. doi: 10.3390/cancers14235921. Cancers (Basel). 2022. PMID: 36497403 Free PMC article.
A novel gene signature unveils three distinct immune-metabolic rewiring patterns conserved across diverse tumor types and associated with outcomes.
Pedrosa L, Foguet C, Oliveres H, Archilla I, de Herreros MG, Rodríguez A, Postigo A, Benítez-Ribas D, Camps J, Cuatrecasas M, Castells A, Prat A, Thomson TM, Maurel J, Cascante M. Pedrosa L, et al. Among authors: oliveres h. Front Immunol. 2022 Sep 2;13:926304. doi: 10.3389/fimmu.2022.926304. eCollection 2022. Front Immunol. 2022. PMID: 36119118 Free PMC article.
A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study.
Español-Rego M, Fernández-Martos C, Elez E, Foguet C, Pedrosa L, Rodríguez N, Ruiz-Casado A, Pineda E, Cid J, Cabezón R, Oliveres H, Lozano M, Ginés A, García-Criado A, Ayuso JR, Pagés M, Cuatrecasas M, Torres F, Thomson T, Cascante M, Benítez-Ribas D, Maurel J. Español-Rego M, et al. Among authors: oliveres h. Cancer Immunol Immunother. 2023 Apr;72(4):827-840. doi: 10.1007/s00262-022-03283-5. Epub 2022 Sep 9. Cancer Immunol Immunother. 2023. PMID: 36083313 Free PMC article.
Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01).
Aparicio J, Virgili Manrique AC, Capdevila J, Muñoz Boza F, Galván P, Richart P, Oliveres H, Páez D, Hernando J, Serrano S, Vera R, Hernandez-Yagüe X, Gallego RÁ, Riesco-Martinez MC, García de Albeniz X, Maurel J. Aparicio J, et al. Among authors: oliveres h. Clin Transl Oncol. 2022 Nov;24(11):2155-2165. doi: 10.1007/s12094-022-02868-x. Epub 2022 Jun 27. Clin Transl Oncol. 2022. PMID: 35761123 Free PMC article. Clinical Trial.
Association of the Lung Immune Prognostic Index with Immunotherapy Outcomes in Mismatch Repair Deficient Tumors.
Auclin E, Vuagnat P, Smolenschi C, Taieb J, Adeva J, Nebot-Bral L, Garcia de Herreros M, Vidal Tocino R, Longo-Muñoz F, El Dakdouki Y, Martín-Romano P, Gaba L, Saurí T, Oliveres H, Castañón E, Garcia-Carbonero R, Besse B, Massard C, Mezquita L, Hollebecque A. Auclin E, et al. Among authors: oliveres h. Cancers (Basel). 2021 Jul 27;13(15):3776. doi: 10.3390/cancers13153776. Cancers (Basel). 2021. PMID: 34359675 Free PMC article.
14 results